• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Novavax COVID-19 vaccine proves effective in trials


In a U.K trial, the drug proved 96 percent efficacy against the original strain of COVID-19.

Novavax COVID-19 vaccine proves effective in trials

Novavax has announced its COVID-19 vaccine, NVX-CoV2373, proved very effective in guarding against the disease.

According to a news release, in a U.K. phase 3 trial in the the vaccine showed 96.4 percent efficacy against mild, moderate, and severe COVID-19 and 100 percent protection from severe disease including hospitalization and death. A phase 2b trial in an area of South Africa where the majority of strains are B1.351 escape variants showed the vaccine had an efficacy of 55.4 percent.

"We are very encouraged by the data showing that NVX-CoV2373 not only provided complete protection against the most severe forms of disease, but also dramatically reduced mild and moderate disease across both trials," Stanley C. Erck, president and CEO of Novavax, says in the release. “Importantly, both studies confirmed efficacy against the variant strains. Today marks one year since the WHO officially declared the COVID-19 pandemic, and with this data in hand, we are even more motivated to advance our vaccine as a potential weapon in the fight to end the suffering caused by COVID-19."

In February, the company announced it would begin rolling reviews by the Food and Drug Administration, Medicines and Healthcare products Regulatory Agency, European Medicines Agency, and Health Canada while Novavax completed its phase 3 trials in the U.K and U.S.

A month prior to that, the company reported the vaccine showed 89.3 percent efficacy in a Phase 3 clinical trial in the U.K. with more than 50 percent of study cases showing the U.K variant, and 60 percent efficacy in a Phase 2b clinical trial in South Africa. More than 90 percent of the cases in this test were the South African variant.

Related Videos
Michael J. Barry, MD
Kalvin Yu, MD
William Cooke, MD, FAAFP, FASAM, AAHIVS, gives expert advice
J. Corey Feist, JD, MBA, gives expert advice